Report cover image

Asia-Pacific Clinical Biomarkers Market - Analysis and Forecast, 2023-2033

Publisher BIS Research
Published Jun 27, 2024
Length 53 Pages
SKU # BIS18925864

Description

Asia-Pacific Clinical Biomarkers Market - Analysis and Forecast, 2023-2033


Introduction to Asia-Pacific Clinical Biomarkers Market

The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.

Market Introduction

The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.

Market Segmentation:

Segmentation 1: by Country

China
India
Japan
South Korea
Australia
Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy:Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy:The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are


BGI
Novogene Co., Ltd.

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 1-5 business days to complete the report upon order confirmation.

Table of Contents

53 Pages
Executive Summary
1 Market
2 Market Scope
2.1 Key Questions Answered in the Report
3 Research Methodology
3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.1.2.1 Open Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling
4 Market Overview
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
4.4 COVID-19 Impact on Clinical Biomarkers Market
4.4.1 COVID-19 Impact on Market Size
4.5 Market Trends
4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
4.5.2 Increasing Biomarkers Usage in Precision Medicine
4.5.3 Technologies Being Used in Clinical Biomarker Testing
4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible
5 Region
5.1 Overview
5.2 Asia-Pacific
5.2.1 China
5.2.2 India
5.2.3 Japan
5.2.4 South Korea
5.2.5 Australia
5.2.6 Rest-of-Asia-Pacific
6 Market - Company Profiles
6.1 Overview
6.2 BGI
6.2.1 Company Overview
6.2.2 Role of BGI in the Clinical Biomarkers Market
6.2.3 Corporate Strategies
6.2.3.1 Product Launch
6.2.4 Analyst’s Perspective
6.3 Novogene Co., Ltd.
6.3.1 Company Overview
6.3.2 Role of Novogene Co., Ltd. in the Clinical Biomarkers Market
6.3.3 Analyst’s Perspective
List of Figures
Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 2: Asia-Pacific Clinical Biomarkers Market Research Methodology
Figure 3: Primary Research Methodology
Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
Figure 5: Top-Down Approach (Segment-Wise Analysis)
Figure 6: Biomarkers Used in Various Clinical Areas
Figure 7: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
Figure 10: Use of Clinical Biomarkers in Personalized Medicine
Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 15: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 16: Asia-Pacific Clinical Biomarkers Market (by Country), $Billion, 2022-2033
Figure 17: Asia-Pacific: Market Dynamics
Figure 18: China Clinical Biomarkers Market, $Billion, 2022-2033
Figure 19: India Clinical Biomarkers Market, $Billion, 2022-2033
Figure 20: Japan Clinical Biomarkers Market, $Billion, 2022-2033
Figure 21: South Korea Clinical Biomarkers Market, $Billion, 2022-2033
Figure 22: Australia Clinical Biomarkers Market, $Billion, 2022-2033
Figure 23: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 24: Total Number of Companies Profiled
Figure 25: BGI: Service Portfolio
Figure 26: Novogene Co., Ltd.: Service Portfolio
List of Tables
Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
Table 2: List of Product/Service Offered and its Technology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us